This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bell-McGuinn, K. M. Articles by Joyce, J. A. Search for Related Content PubMed PubMed Citation Articles by Bell-McGuinn, K. M. Articles by Joyce, J. A.

Inhibition of Cysteine Cathepsin Protease Activity Enhances Chemotherapy Regimens by Decreasing Tumor Growth and Invasiveness in a Mouse Model of Multistage Cancer

¹ Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York; ² Departments of Pathology, Microbiology and Immunology, Stanford School of Medicine, Stanford, California; and ³ Department of Biochemistry and Biophysics, Diabetes Center, and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California

Requests for reprints: Johanna A. Joyce, Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, Box 372, 1275 York Avenue, New York, NY 10021. Phone: 646-888-2048; Fax: 646-422-0231; E-mail: joycej{at}mskcc.org.

Increases in protease expression and activity are associated with malignant progression and poor patient prognosis in a number of human cancers. Members of the papain family of cysteine cathepsins are among the protease classes that have been functionally implicated in cancer. Inhibition of the cysteine cathepsin family using a pan-cathepsin inhibitor, JPM-OEt, led to tumor regression in the RIP1-Tag2 (RT2) mouse model of pancreatic islet cell tumorigenesis. The present study was designed to determine whether this cathepsin inhibitor, when used in combination with chemotherapy, would increase antitumor efficacy. RT2 mice were treated in a late-stage regression trial with three different chemotherapy regimens, alone or in combination with the cathepsin inhibitor, JPM-OEt. Cyclophosphamide was administered in either a maximum tolerated dose (MTD) regimen, a "metronomic" continuous low-dose regimen, or a "chemo-switch" regimen consisting of MTD followed by metronomic dosing. Mice were sacrificed at a defined end point and tumor burden was assessed followed by a detailed analysis of cell proliferation, apoptosis, vascularization, and invasiveness in the treated and control lesions. An additional cohort of mice was followed for survival analysis. The cathepsin inhibitor plus the chemo-switch regimen of cyclophosphamide led to the most pronounced reduction in tumor burden and greatest increase in overall survival. Cysteine cathepsin inhibition resulted in a significant decrease in tumor invasiveness, which was further augmented in combination with each of the chemotherapy dosing regimens. These results encourage the development and continuing evaluation of cysteine cathepsin inhibitors as cancer therapeutics. [Cancer Res 2007;67(15):7378–85]

This article has been cited by other articles:

				R. E. Burden, J. A. Gormley, T. J. Jaquin, D. M. Small, D. J. Quinn, S. M. Hegarty, C. Ward, B. Walker, J. A. Johnston, S. A. Olwill, et al. Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis Clin. Cancer Res., October 1, 2009; 15(19): 6042 - 6051. [Abstract] [Full Text] [PDF]

				C. LINDAHL, M. SIMONSSON, A. BERGH, E. THYSELL, H. ANTTI, M. SUND, and P. WIKSTROM Increased Levels of Macrophage-secreted Cathepsin S during Prostate Cancer Progression in TRAMP Mice and Patients Cancer Genomics Proteomics, May 1, 2009; 6(3): 149 - 159. [Abstract] [Full Text] [PDF]

				C. G. Kleer, N. Bloushtain-Qimron, Y.-H. Chen, D. Carrasco, M. Hu, J. Yao, S.-K. Kraeft, L. C. Collins, M. S. Sabel, P. Argani, et al. Epithelial and Stromal Cathepsin K and CXCL14 Expression in Breast Tumor Progression Clin. Cancer Res., September 1, 2008; 14(17): 5357 - 5367. [Abstract] [Full Text] [PDF]